Silence Therapeutics PLC (LON:SLN) has made a clinical trial application for its lead candidate, which is being developed to treat iron overload disorders.
SLN124 already has orphan drug designation in Europe, which could shorten its timeline to market while providing the approved product with additional exclusivity.
“Promising candidate medicine”
Silence describes SLN124 as a “promising candidate medicine” for patients with iron overload disorders such as ß -Thalassemia, Myelodysplastic Syndrome and Hereditary Hemochromatosis.
A phase Ib, first-in-human trial is scheduled to start in the third quarter.
Chief executive, Dr David Horn Solomon, said the submission was a “very positive step forward” as Silence continued preparations for its return to the clinic.
“With robust data generated in several preclinical disease models, favourable safety profile and patient-friendly administration, we believe that SLN124 is well positioned against the current standard of care and other medicines in development for the treatment of iron overload disorders.”